NP_899156.1
[Other Products]
NCBI GenBank Nucleotide #
|
[Other Products]
UniProt Primary Accession #
|
[Other Products]
UniProt Related Accession #
Molecular Weight
54,077 Da
NCBI Official Full Name
gamma-aminobutyric acid receptor subunit gamma-2
NCBI Official Synonym Full Names
gamma-aminobutyric acid (GABA) A receptor, gamma 2
NCBI Protein Information
gamma-aminobutyric acid receptor subunit gamma-2; GABA(A) receptor subunit gamma-2; gamma-aminobutyric acid A receptor, gamma 2; gamma-aminobutyric acid A receptor, gamma 2; gamma-aminobutyric acid (GABA-A) receptor, subunit gamma 2
UniProt Protein Name
Gamma-aminobutyric acid receptor subunit gamma-2
UniProt Synonym Protein Names
GABA(A) receptor subunit gamma-2
UniProt Entry Name
GBRG2_RAT
NCBI Summary for GABRG2
subunit of GABA receptors, which bind benzodiazepines and act as inhibitory ion channels in the brain [RGD, Feb 2006]
UniProt Comments for GABRG2
GABRG2 iso2: GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. Defects in GABRG2 are the cause of childhood absence epilepsy type 2 (ECA2). ECA2 is a subtype of idiopathic generalized epilepsy (IGE) characterized by an onset at age 6-7 years, frequent absence seizures (several per day) and bilateral, synchronous, symmetric 3-Hz spike waves on EEG. During adolescence, tonic-clonic and myoclonic seizures develop. Some individuals manifest ECA2 occurring in combination with febrile convulsions. Defects in GABRG2 are the cause of familial febrile convulsions type 8 (FEB8). A febrile convulsion is defined as a seizure event in infancy or childhood, usually occurring between 6 months and 6 years of age, associated with fever but without any evidence of intracranial infection or defined pathologic or traumatic cause. Febrile convulsions affect 5-12% of infants and children up to 6 years of age. There is epidemiological evidence that febrile seizures are associated with subsequent afebrile and unprovoked seizures in 2% to 7% of patients. Defects in GABRG2 are the cause of generalized epilepsy with febrile seizures plus type 3 (GEFS+3). Generalized epilepsy with febrile seizures-plus refers to a rare autosomal dominant, familial condition with incomplete penetrance and large intrafamilial variability. Patients display febrile seizures persisting sometimes beyond the age of 6 years and/or a variety of afebrile seizure types. GEFS+ is a disease combining febrile seizures, generalized seizures often precipitated by fever at age 6 years or more, and partial seizures, with a variable degree of severity. Defects in GABRG2 are a cause of severe myoclonic epilepsy in infancy (SMEI); also called Dravet syndrome. SMEI is a rare disorder characterized by generalized tonic, clonic, and tonic-clonic seizures that are initially induced by fever and begin during the first year of life. Later, patients also manifest other seizure types, including absence, myoclonic, and simple and complex partial seizures. Psychomotor development delay is observed around the second year of life. SMEI is considered to be the most severe phenotype within the spectrum of generalized epilepsies with febrile seizures-plus. Belongs to the ligand-gated ion channel (TC 1.A.9) family. Gamma-aminobutyric acid receptor (TC 1.A.9.5) subfamily. GABRG2 sub-subfamily. 2 isoforms of the human protein are produced by alternative splicing.
Protein type: Channel, chloride; Membrane protein, multi-pass; Membrane protein, integral; Transporter, ion channel; Transporter; Channel, ligand-gated
Cellular Component: postsynaptic membrane; axon; integral to plasma membrane; cytoplasm; cell junction
Molecular Function: chloride channel activity; protein binding; GABA-A receptor activity; GABA receptor activity; inhibitory extracellular ligand-gated ion channel activity
Biological Process: synaptic transmission; adult behavior; synaptic transmission, GABAergic; chloride transport; signal transduction; gamma-aminobutyric acid signaling pathway; post-embryonic development
Research Articles on GABRG2
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice. It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
Pathways associated with GABRG2 elisa kit
Diseases associated with GABRG2 elisa kit
Organs/Tissues associated with GABRG2 elisa kit
|